DRG Market Assessment reports

What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…

TreatmentTrends: Psoriasis (EU) will cover practice dynamics, current use and future use projections for key products, perceived product ad-vantages and disadvantages. While the report does cover…

This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million…

The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…

Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…

Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…

To view the recording from our webinar series, please select the video link to the left   Outline – Background – Overarching theme of the EGA conference – Current and future startegies to drive…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…